Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
9.39M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
1.92M
-
Shares change
-
+1.92M
-
Total reported value, excl. options
-
$44.4M
-
Value change
-
+$44.4M
-
Number of buys
-
47
-
Price
-
$23.33
Significant Holders of Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share (TVRD) as of Q2 2025
48 filings reported holding TVRD - Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q2 2025.
Tvardi Therapeutics, Inc. - Common stock, par value $0.001 per share (TVRD) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.92M shares
of 9.39M outstanding shares and own 20.48% of the company stock.
Largest 10 shareholders include Slate Path Capital LP (704K shares), VANGUARD GROUP INC (398K shares), BlackRock, Inc. (268K shares), 683 Capital Management, LLC (176K shares), GEODE CAPITAL MANAGEMENT, LLC (112K shares), FARALLON CAPITAL MANAGEMENT LLC (43.2K shares), STATE STREET CORP (41.5K shares), RENAISSANCE TECHNOLOGIES LLC (31.2K shares), NORTHERN TRUST CORP (30.4K shares), and UBS Group AG (29.4K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.